Cytosorbents Corp CTSO
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-23.5
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $37.1M | -$8.2M | $26.5M | -$12.5M | $5.9M |
| 2024 | $35.6M | -$20.7M | $24.9M | -$14.7M | $11.1M |
| 2023 | $31.1M | -$29.2M | $22.0M | -$22.2M | $23.5M |
| 2022 | $34.7M | -$32.8M | $20.7M | -$34.3M | $35.4M |
| 2021 | $43.2M | -$24.6M | $32.1M | -$17.6M | $62.6M |
| 2020 | $41.0M | -$7.8M | $30.0M | -$6.3M | $79.2M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -23.5 (distress)
- Working capital / assets 0.247
- Retained earnings / assets -7.066
- EBIT / assets -0.334
- Equity / liabilities 0.154
Source: SEC EDGAR filings · CIK 0001175151 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.